论文信息 - Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study - 字舞流文

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor | S. Tolaney | C. Jochems | P. Tarantino | H. Parsons | N. Denduluri | F. Lynce | M. Gatti-Mays | C. Gallagher | N. Toney | J. Zeck | R. Kaltman | D. Graham | I. Schlam | S. Tiwari | Ami Chitalia | C. Mainor | Jeffrey Schlom | Xue Geng | S. M. Swain | Raquel Nunes | Claudine Isaacs | Renee N. Donahue | Greg Jones | Hongkun Wang | Rita Nanda | Julie Collins | Katia Khoury | Paula Pohlmann